Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Fredrik Erlandsson"'
Autor:
Susanne Johansson, David Han, Thomas Hunt, Karin Björck, Delia Florica, Michael Gillen, Jesse Hall, Fredrik Erlandsson
Publikováno v:
Pharmacology Research & Perspectives, Vol 10, Iss 3, Pp n/a-n/a (2022)
Abstract Verinurad is a selective inhibitor of uric acid transporter 1 (URAT1). Here, we assessed the safety, pharmacokinetics, and pharmacodynamics of verinurad + allopurinol and verinurad monotherapy in healthy participants. Studies 1 (NCT03836599)
Externí odkaz:
https://doaj.org/article/d64731bbf52f4f1998a9d8245b33bc2f
Publikováno v:
Entropy, Vol 19, Iss 12, p 686 (2017)
[-15]With the growing use of popular social media services like Facebook and Twitter it is challenging to collect all content from the networks without access to the core infrastructure or paying for it. Thus, if all content cannot be collected one m
Externí odkaz:
https://doaj.org/article/7bb02df6ac694e67b77061418fdde322
Publikováno v:
Entropy, Vol 18, Iss 5, p 164 (2016)
Influential users play an important role in online social networks since users tend to have an impact on one other. Therefore, the proposed work analyzes users and their behavior in order to identify influential users and predict user participation.
Externí odkaz:
https://doaj.org/article/1d5f2f9de2b7482f873e313a2c92eb90
Autor:
Lesley A. Inker, Hiddo J.L. Heerspink, Tord Rikte, Shira Perl, Sapphire investigators, Tom Greene, Vlado Perkovic, Magnus K. Bjursell, Fredrik Erlandsson, Robert Terkeltaub, Austin G. Stack
Publikováno v:
Nephrology Dialysis Transplantation, 37(8), 1461-1471. Oxford University Press
Background Verinurad is a human uric acid (UA) transporter (URAT1) inhibitor known to decrease serum UA (sUA) levels and that may reduce albuminuria. In a Phase 2a study (NCT03118739), treatment with verinurad + febuxostat lowered urine albumin-to-cr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0349af96a20cbaf55ac84e88f6d44eb5
https://doi.org/10.1093/ndt/gfab237
https://doi.org/10.1093/ndt/gfab237
Autor:
Robert Terkeltaub, Susanne Johansson, Fredrik Erlandsson, Austin G. Stack, Joanna Parkinson, Nalina Dronamraju, Eva Johnsson
Publikováno v:
American Journal of Kidney Diseases. 77:481-489
Rationale & Objective Hyperuricemia has been implicated in the development and progression of chronic kidney disease. Verinurad is a novel, potent, specific urate reabsorption inhibitor. We evaluated the effects on albuminuria of intensive urate-lowe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc821dc41dcedee8593cf63b8760729b
https://doi.org/10.1053/j.ajkd.2020.09.009
https://doi.org/10.1053/j.ajkd.2020.09.009
Autor:
Susanne Johansson, David Han, Thomas Hunt, Karin Björck, Delia Florica, Michael Gillen, Jesse Hall, Fredrik Erlandsson
Publikováno v:
Pharmacology researchperspectives. 10(3)
Verinurad is a selective inhibitor of uric acid transporter 1 (URAT1). Here, we assessed the safety, pharmacokinetics, and pharmacodynamics of verinurad + allopurinol and verinurad monotherapy in healthy participants. Studies 1 (NCT03836599) and 2 (N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13043f13ec594f26e58854b692413d71
https://pubmed.ncbi.nlm.nih.gov/35593744
https://pubmed.ncbi.nlm.nih.gov/35593744
Publikováno v:
American Journal of Kidney Diseases. 78:468-469
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b46e36c4df39500f1ddcc566a93a852
https://doi.org/10.1053/j.ajkd.2021.05.009
https://doi.org/10.1053/j.ajkd.2021.05.009
Autor:
Caroline A. Lee, V. Sashi Gopaul, Constanze Hilgendorf, Tommy B. Andersson, Susanne Johansson, Anna Vildhede, Fredrik Erlandsson
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 378(2)
Verinurad is a selective uric acid transporter 1 (URAT1) inhibitor in development for the treatment of chronic kidney disease and heart failure. In humans, two major acyl glucuronide metabolites have been identified: direct glucuronide M1 and N-oxide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1b8f349b1f97e87c5b602afb50b2b81
https://pubmed.ncbi.nlm.nih.gov/34074714
https://pubmed.ncbi.nlm.nih.gov/34074714
Autor:
Fredrik Bååthe, Fredrik Erlandsson, Erichsen Andersson, Ewa Wikström, Kerstin Nilsson, Axel Wolf
BackgroundValue-based healthcare (VBHC) argues healthcare needs to be refocused to maximize value creation, defining value as the value quota (VQ) of outcomes important for the patient divided by the cost of the care. Value is central to the VBHC con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7eab36c0458f92b6b172ca6251426bf
https://doi.org/10.21203/rs.3.rs-25056/v1
https://doi.org/10.21203/rs.3.rs-25056/v1
Autor:
M Kjaer, Krister Bamberg, Hans Ericsson, Linda Wernevik, Judith Hartleib-Geschwindner, Karin Nelander, Fredrik Erlandsson, Rasmus Jansson-Löfmark, Muna Albayaty, Carl Amilon, Ligia Chialda
Publikováno v:
British Journal of Clinical Pharmacology. 84:1486-1493
Aims AZD9977 is the first mineralocorticoid receptor modulator in clinical development exerting similar organ protection as eplerenone with minimal urinary electrolyte effects in preclinical studies. The aim was to perform the initial clinical assess
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::22998e7eab0e9f69d707fef6451e06f7
https://doi.org/10.1111/bcp.13562
https://doi.org/10.1111/bcp.13562